Novartis Home

Novartis scientist working in a lab

At Novartis, we are reimagining medicine

Novartis reinforces commitment to patient access, pricing a EUR 1.85 billion sustainability-linked bond

Read More

ESG - Committed to increasing access

Novartis reinforces commitment to patient access, pricing a EUR 1.85 billion sustainability-linked bond, a first in the healthcare industry.

Learn More

Environmental, Social and Governance (ESG)

Novartis aims to hold itself to the highest standards of sustainability and ethical business practices. We take bold steps to increase access to medicines, tackle complex global health challenges, and do our part as a responsible corporate citizen.

Learn More

Novartis COVID-19 Information Center

Novartis is responding to the coronavirus disease (COVID-19) outbreak. The information center provides a central hub for news, guidance and resources.

Enter

Novartis at ESMO

Find the latest oncology resources on Novartis data featured at the European Society for Medical Oncology (ESMO).

Read More

AveXis renamed Novartis Gene Therapies, signifying the growing importance of gene therapy to Novartis corporate strategy

Learn More

Our commitment to doing what's right

Novartis is committed to ensuring our associates are empowered to do what’s right. On September 01, 2020, we introduced a new Code of Ethics for Novartis.

Learn More